# EDGAR Filing Document

**Accession Number:** 0001023549
**File Stem:** 0001213900-25-121299
**Filing Date:** 2025-12
**Character Count:** 2552
**Document Hash:** 5a62487f7bd2b7fc3a21a16c0874dc8b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-121299.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001213900-25-121299

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251212

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XTL BIOPHARMACEUTICALS LTD
- **CENTRAL INDEX KEY:** 0001023549
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36000
- **FILM NUMBER:** 251569190

**BUSINESS ADDRESS:**
- **STREET 1:** XTL BIOPHARMACEUTICALS LTD
- **STREET 2:** C/O ALSTON & BIRD LLP, 90 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 972 9 955 7080

**MAIL ADDRESS:**
- **STREET 1:** 26 BEN-GURION ST.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5112001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of December 2025

Commission File Number: **001-36000**

**XTL Biopharmaceuticals Ltd.** 

(Translation of registrant's name into English)

**26 Ben-Gurion St.**

**Ramat Gan,<br> 5112001, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

XTL Biopharmaceuticals Ltd. (the "Company") announces that on December 11, 2025, Tal Klinger, Chief Executive Officer of Social Proxy Ltd., an Israeli company and wholly owned subsidiary of the Company, and Roee Klinger, Chief Technology Officer of Social Proxy Ltd., submitted a letter of resignation from their respective positions, effective immediately.

The Company is evaluating next steps with respect to the management of Social Proxy Ltd. and will provide updates as appropriate.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **XTL BIOPHARMACEUTICALS LTD.** | **XTL BIOPHARMACEUTICALS LTD.** |
| Date: December 12, 2025 | By: | /s/ Noam Band |
|  |  | Noam Band |
|  |  | Chief Executive Officer |

---